Partner Headlines - GSK

  1. Trump + Stocks: The Week In Review

    TalkMarkets
  2. Last London Letter

    TalkMarkets
  3. Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle

    Investors Business Daily
  4. Merck (MRK) Does Well In 2016: Reasons For Outperformance

    TalkMarkets
  5. These 8 Top Dividend Stocks Are Also ADRs - Check Them Out

    TalkMarkets
  6. BP: Asset Sales, New Projects Fuel Its 6.7% Dividend Yield

    TalkMarkets
  7. GlaxoSmithKline: Robust Pipeline Supports its 5.5% Dividend Yield

    TalkMarkets
  8. GSK: Robust Pipeline Supports its 5.5% Dividend Yield

    TalkMarkets
  9. Better Than The Maestro

    TalkMarkets
  10. 6 Worthy Dividend Stocks Down 10% Or More

    TalkMarkets
  11. Musings And Global Markets

    TalkMarkets
  12. Trump Triumphs

    TalkMarkets
  13. Pharmaceutical Stocks Surge After Republican Victory

    TalkMarkets
  14. Week In Review: China Healthcare And Pharma Deals

    TalkMarkets
  15. Global Roundup: Roche, Vale, Novo Nordisk, Teva, Benitec Et Al ...

    TalkMarkets
  16. Week In Review: China Resources Pharma To Price $2 Billion Hong ...

    TalkMarkets
  17. Seven Sources of Competitive Advantage

    TalkMarkets
  18. The Internet Of Medical Things: 6 Stocks In Focus

    TalkMarkets
  19. Alphabet-Glaxo Joint Venture Targets 'Bioelectronics'

    Investors Business Daily
  20. Veeva Is Key Partner In Big Pharma's Race Against The Clock

    Investors Business Daily
  21. Stock Futures Up, Gaining Strength; Apple Hauls Techs Higher

    Investors Business Daily
  22. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  23. Getting to Know VBI Vaccines

    GuruFocus
  24. Brandes Makes a Variety of Reductions in 4th Quarter

    GuruFocus
  25. Stock Futures Up As Oil Behaves; Syngenta Up On ChemChina Deal

    IBD
  26. EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, ...

    Benzinga
  27. Benzinga's M&A Chatter for Thursday January 28, 2015

    Benzinga
  28. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  29. Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

    GuruFocus
  30. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  31. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  32. Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  33. Cisco Systems, Microsoft and Intel Bring High Dividend Yields ...

    GuruFocus
  34. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  35. High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox ...

    GuruFocus
  36. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  37. John Rogers' Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  38. 3 Global Investment Ideas From Gurus

    GuruFocus
  39. Relypsa Stock Jumps On Buyout Rumors

    IBD
  40. Skin Disease Drug Costs Jump

    IBD
  41. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD
  42. Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline

    GuruFocus
  43. 3 Investment Ideas of Ariel Investment's Rupal Bhansali

    GuruFocus
  44. Pfizer to Create a New Pharmaceutical Colossus

    GuruFocus
  45. GlaxoSmithKline

    IBD
  46. Gilead Beats Q3 Estimates As HIV Franchise Shines

    IBD
  47. ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase ...

    Benzinga
  48. Benzinga's Top Upgrades

    Benzinga
  49. IBM, Schlumberger PTs Lowered; Valeant Downgraded

    IBD
  50. GlaxoSmithKline Has a High (and Dangerous) Dividend Yield

    GuruFocus
  51. Tweedy Browne Global Value Adds to Stake in GlaxoSmithKline

    GuruFocus
  52. Liquidia Technologies And GlaxoSmithKline Advance Existing Collaboration; ...

    Benzinga
  53. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  54. Regulatory Update: GSK and Theravance Announce Intention to File ...

    GuruFocus
  55. Guru Stocks at 52-Week Lows: RDS.A, PTR, UL, BP, GSK

    GuruFocus
  56. Five Prime Therapeutics Announces Initial Data From Ongoing Phase ...

    Benzinga
  57. GSK and Theravance Announce Results From the SUMMIT COPD CV Survival ...

    GuruFocus
  58. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  59. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  60. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  61. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  62. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  63. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  64. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  65. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  66. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  67. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  68. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  69. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  70. Benzinga's Volume Movers

    Benzinga
  71. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  72. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  73. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  74. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  75. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  76. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  77. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  78. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  79. Axovant IPO Best In 20 Years

    IBD
  80. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  81. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  82. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  83. Perrigo buys Glaxo OTC drugs

    IBD
  84. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  85. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  86. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  87. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  88. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  89. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  90. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  91. Glaxo more bullish than Q1

    IBD
  92. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  93. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  94. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  95. GlaxoSmithKline

    IBD
  96. Novartis EPS beats the Street

    IBD
  97. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  98. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  99. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  100. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
Trading Center